

**WG23-08**

**NATIONAL HEALTH  
SERVICE (WALES) ACT 2006**

**LOCAL HEALTH BOARDS AND  
NHS TRUSTS REPORTING ON  
THE INTRODUCTION OF NEW  
MEDICINES INTO THE  
NATIONAL HEALTH SERVICE  
IN WALES DIRECTIONS 2023**

*Made*

\*\*\*

*Coming into force*

*1 April 2023*

The Welsh Ministers, in exercise of the powers conferred on them by sections 12(3), 19(1) and 203(9) and (10) of the National Health Service (Wales) Act 2006, give the following Directions.

**Title, commencement, application and interpretation**

1.—(1) The title of these Directions is the Local Health Boards and NHS Trusts Reporting on the Introduction of New Medicines into the National Health Service in Wales Directions 2023.

(2) These Directions come into force on 1 April 2023 and apply to every Local Health Board and NHS Trust in Wales.

(3) In these Directions—

“AWMSG” (“GSFCG”) means the All Wales Medicines Strategy Group;

“High-Cost Drugs Reporting System” (“*System Adrodd am Gyffuriau Cost Uchel*”) means the system approved by Welsh Ministers for capturing information about the use of high-cost drugs.

**Implementation of the High-Cost Drugs Reporting System**

2. Unless directed otherwise by the Welsh Ministers, Local Health Boards and NHS Trusts must use the High-Cost Drugs Reporting System on each occasion a medicine included in the list of medicines approved by the AWMMSG<sup>(1)</sup> is—

- (a) prescribed for any patient on a prescription form for the purpose of a patient's NHS treatment; or
- (b) supplied or administered to any patient for the purpose of the patient's NHS treatment.

Signed on behalf of the Minister for Health and Social Services, one of the Welsh Ministers.

Dated 21<sup>st</sup> April 2023



*Andrew Evans*

Chief Pharmaceutical Officer

Welsh Government

---

(1) The list of approved medicines is available at: